METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER

被引：22
|
作者：
Fontana, Andrea [1 ,2 ]
Bocci, Guido [3 ]
Galli, Luca [1 ,2 ]
D'Arcangelo, Manolo
Derosa, Lisa [1 ,2 ]
Fioravanti, Anna [3 ]
Orlandi, Paola [3 ]
Barletta, Maria Teresa
Landi, Lorenza
Bursi, Simona
Minuti, Gabriele
Bona, Eleonora [1 ,2 ]
Grazzini, Ilaria [1 ,2 ]
Danesi, Romano [3 ]
Falcone, Alfredo [1 ,2 ]
机构：
[1] Univ Pisa, Azienda Osped Univ Pisana, Ist Toscano Tumori, Unit Med Oncol 2, Pisa, Italy
[2] Univ Pisa, Dept Oncol Transplants & New Technol Med, Pisa, Italy
[3] Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Pisa, Italy
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2010年 / 58卷 / 05期
关键词：
DOCETAXEL; DEXAMETHASONE; MITOXANTRONE; PREDNISONE;
D O I：
10.1111/j.1532-5415.2010.02833.x
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：986 / 988
页数：3
相关论文
共 50 条
  • [1] Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
    Tobias Peres
    Stefanie Aeppli
    Stefanie Fischer
    Katrin Gysel
    Christian Rothermundt
    Journal of Cancer Research and Clinical Oncology, 150
  • [2] Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
    Peres, Tobias
    Aeppli, Stefanie
    Fischer, Stefanie
    Gysel, Katrin
    Rothermundt, Christian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)
  • [3] ORAL METRONOMIC CYCLOPHOSPHAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR DOCETAXEL THERAPY
    Barroso-Sousa, R.
    Chaves, A. C. R.
    Fonseca, L. G.
    De Castro, G., Jr.
    Dzik, C.
    Hoff, P. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 308
  • [4] Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer
    Caffo, Orazio
    Facchini, Gaetano
    Biasco, Elisa
    Ferrau, Francesco
    Morelli, Franco
    Donini, Maddalena
    Buttigliero, Consuelo
    Calvani, Nicola
    Guida, Annalisa
    Chiuri, Vincenzo Emanuele
    Basso, Umberto
    Mucciarini, Claudia
    Conteduca, Vincenza
    Rossetti, Sabrina
    Veccia, Antonello
    Maines, Francesca
    Kinspergher, Stefania
    De Giorgi, Ugo
    FUTURE ONCOLOGY, 2019, 15 (10) : 1115 - 1123
  • [5] Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer
    Cardillo, Irene
    Spugnini, Enrico P.
    Galluzzo, Paola
    Contestabile, Michela
    Dell'Anna, Maria Lucia
    Picardo, Mauro
    Crispi, Stefania
    Calogero, Raffaele A.
    Piccolo, Maria Teresa
    Arigoni, Maddalena
    Cantarella, Daniela
    Boccellino, Mariarosaria
    Quagliuolo, Lucio
    Ferretti, Gianluigi
    Carlini, Paolo
    Felici, Alessandra
    Boccardo, Francesco
    Cognetti, Francesco
    Baldi, Alfonso
    FUTURE ONCOLOGY, 2013, 9 (09) : 1375 - 1388
  • [6] Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Fea, E.
    Vanella, P.
    Miraglio, E.
    Cauchi, C.
    Colantonio, I.
    Denaro, N.
    Di Costanzo, G.
    Garrone, O.
    Granetto, C.
    Occelli, M.
    Ricci, V.
    Vandone, A. M.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
    Romualdo Barroso-Sousa
    Leonardo Gomes da Fonseca
    Karla Teixeira Souza
    Ana Carolina Ribeiro Chaves
    Ariel Galapo Kann
    Gilberto de Castro
    Carlos Dzik
    Medical Oncology, 2015, 32
  • [8] Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).
    Wang, Jue
    McGuire, Timothy R.
    Schwarz, James K.
    Meza, Jane L.
    Talmadge, James E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [9] Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
    Barroso-Sousa, Romualdo
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Ribeiro Chaves, Ana Carolina
    Kann, Ariel Galapo
    de Castro, Gilberto, Jr.
    Dzik, Carlos
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 6
  • [10] VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
    Orlandi, P.
    Fontana, A.
    Fioravanti, A.
    Di Desidero, T.
    Galli, L.
    Derosa, L.
    Canu, B.
    Marconcini, R.
    Biasco, E.
    Solini, A.
    Francia, G.
    Danesi, R.
    Falcone, A.
    Bocci, G.
    BRITISH JOURNAL OF CANCER, 2013, 109 (04) : 957 - 964
12345